210 related articles for article (PubMed ID: 22984537)
1. Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
Sharp SY; Roe SM; Kazlauskas E; Cikotienė I; Workman P; Matulis D; Prodromou C
PLoS One; 2012; 7(9):e44642. PubMed ID: 22984537
[TBL] [Abstract][Full Text] [Related]
2. Improving the Hsp90 Inhibitors Containing 4-(2,4-Dihydroxyphenyl)-1,2,3-thiadiazole Scaffold: Synthesis, Affinity and Effect on Cancer Cells.
Kazlauskas E; Brukstus A; Petrikas H; Petrikaite V; Cikotiene I; Matulis D
Anticancer Agents Med Chem; 2017 Nov; 17(11):1593-1603. PubMed ID: 28270068
[TBL] [Abstract][Full Text] [Related]
3. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.
Sharp SY; Boxall K; Rowlands M; Prodromou C; Roe SM; Maloney A; Powers M; Clarke PA; Box G; Sanderson S; Patterson L; Matthews TP; Cheung KM; Ball K; Hayes A; Raynaud F; Marais R; Pearl L; Eccles S; Aherne W; McDonald E; Workman P
Cancer Res; 2007 Mar; 67(5):2206-16. PubMed ID: 17332351
[TBL] [Abstract][Full Text] [Related]
4. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
Koay YC; Wahyudi H; McAlpine SR
Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues.
Sharp SY; Prodromou C; Boxall K; Powers MV; Holmes JL; Box G; Matthews TP; Cheung KM; Kalusa A; James K; Hayes A; Hardcastle A; Dymock B; Brough PA; Barril X; Cansfield JE; Wright L; Surgenor A; Foloppe N; Hubbard RE; Aherne W; Pearl L; Jones K; McDonald E; Raynaud F; Eccles S; Drysdale M; Workman P
Mol Cancer Ther; 2007 Apr; 6(4):1198-211. PubMed ID: 17431102
[TBL] [Abstract][Full Text] [Related]
6. 5-Aryl-4-(5-substituted-2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of Hsp90 chaperone.
Cikotiene I; Kazlauskas E; Matuliene J; Michailoviene V; Torresan J; Jachno J; Matulis D
Bioorg Med Chem Lett; 2009 Feb; 19(4):1089-92. PubMed ID: 19168355
[TBL] [Abstract][Full Text] [Related]
7. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
8. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
9. Thermodynamics of aryl-dihydroxyphenyl-thiadiazole binding to human Hsp90.
Kazlauskas E; Petrikaitė V; Michailovienė V; Revuckienė J; Matulienė J; Grinius L; Matulis D
PLoS One; 2012; 7(5):e36899. PubMed ID: 22655030
[TBL] [Abstract][Full Text] [Related]
10. Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90.
Shin SC; El-Damasy AK; Lee JH; Seo SH; Kim JH; Seo YH; Lee Y; Yu JH; Bang EK; Kim EE; Keum G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317068
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs.
Geng K; Liu H; Song Z; Zhang C; Zhang M; Yang H; Cao J; Geng M; Shen A; Zhang A
Eur J Med Chem; 2018 May; 152():76-86. PubMed ID: 29698859
[TBL] [Abstract][Full Text] [Related]
12. Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.
Bargiotti A; Musso L; Dallavalle S; Merlini L; Gallo G; Ciacci A; Giannini G; Cabri W; Penco S; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Barbarino M; Pisano C; Giommarelli C; Zuco V; De Cesare M; Zunino F
Eur J Med Chem; 2012 Jul; 53():64-75. PubMed ID: 22538015
[TBL] [Abstract][Full Text] [Related]
13. Understanding the Hsp90
Magwenyane AM; Mhlongo NN; Lawal MM; Amoako DG; Somboro AM; Sosibo SC; Shunmugam L; Khan RB; Kumalo HM
Molecules; 2020 Apr; 25(8):. PubMed ID: 32295059
[TBL] [Abstract][Full Text] [Related]
14. Detection of the ATPase activity of the molecular chaperones Hsp90 and Hsp72 using the TranscreenerTM ADP assay kit.
Rowlands M; McAndrew C; Prodromou C; Pearl L; Kalusa A; Jones K; Workman P; Aherne W
J Biomol Screen; 2010 Mar; 15(3):279-86. PubMed ID: 20147598
[TBL] [Abstract][Full Text] [Related]
15. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
Eccles SA; Massey A; Raynaud FI; Sharp SY; Box G; Valenti M; Patterson L; de Haven Brandon A; Gowan S; Boxall F; Aherne W; Rowlands M; Hayes A; Martins V; Urban F; Boxall K; Prodromou C; Pearl L; James K; Matthews TP; Cheung KM; Kalusa A; Jones K; McDonald E; Barril X; Brough PA; Cansfield JE; Dymock B; Drysdale MJ; Finch H; Howes R; Hubbard RE; Surgenor A; Webb P; Wood M; Wright L; Workman P
Cancer Res; 2008 Apr; 68(8):2850-60. PubMed ID: 18413753
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and pharmacological evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors.
Liang C; Wu X; Li Z; Zhu J; Lu C; Shen Y
Eur J Med Chem; 2018 Jan; 143():85-96. PubMed ID: 29172085
[TBL] [Abstract][Full Text] [Related]
17. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of HSP90 in melanoma.
Mielczarek-Lewandowska A; Hartman ML; Czyz M
Apoptosis; 2020 Feb; 25(1-2):12-28. PubMed ID: 31659567
[TBL] [Abstract][Full Text] [Related]
19. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
[TBL] [Abstract][Full Text] [Related]
20. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]